Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences:
2026 Jefferies Global Healthcare Conference
1x1 Meetings: Tuesday, June 2
New York, NY
Evercore 2026 Emerging Private Biotech Conference
Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET
Newport, RI
About Ollin Biosciences
Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260526926052/en/
Media:
Katie Engleman
1AB
katie@1abmedia.com
